MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm15197595

Медицинская библиотека · Journal of clinical medicine · 2026

Ketoacidosis at Hypoglycemic and Low Glucose Levels Associated with SGLT2 Inhibitor Use: A Descriptive Systematic Review of Published Cases.

Itagaki Hideya, Endo Tomoyuki

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Background/

Objectives

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly used for heart failure and chronic kidney disease beyond type 2 diabetes, increasing exposure among people without diabetes. Ketoacidosis is a recognized complication, but presentations at low blood glucose (<100 mg/dL) fall outside the familiar euglycemic diabetic ketoacidosis (DKA) alert and are easily missed. We aimed to describe the clinical phenotype of such cases; this review was not registered.

Methods

We systematically searched PubMed and Web of Science (to 25 June 2026) and included only peer-reviewed case reports and case series describing ketoacidosis with a documented blood glucose <100 mg/dL at or near diagnosis during ongoing SGLT2 inhibitor use or within approximately two weeks after discontinuation. Reporting completeness was assessed with the CARE (Case Report) checklist; analyses were descriptive.

Results

Fifteen cases met the criteria (median age 61 years; 6/15 nondiabetic; 6/15 receiving it for heart failure). Median glucose was 68 mg/dL (n = 15; 10/15 <70). Metabolic acidosis was frequently marked (median pH 7.17 [n = 14], anion gap 19.9 [n = 13], β-hydroxybutyrate 5.0 mmol/L [n = 11]). Fasting or poor oral intake was the commonest precipitant (11/15). Among six cases with extractable timing, three occurred within 24 h. Blood glucose was not correlated with β-hydroxybutyrate in this small exploratory sample (Spearman ρ = -0.20; n = 11; p = 0.56). One death occurred (aspiration).

Conclusions

This descriptive synthesis characterizes ketoacidosis occurring at hypoglycemic and low glucose levels reported in SGLT2 inhibitor users, including nondiabetic and cardiorenal patients. The design cannot establish incidence, risk, or causality (very low certainty of evidence); clinicians should nonetheless consider ketoacidosis in exposed patients with anion-gap acidosis or ketosis even without hyperglycemia.

Для цитирования: Itagaki Hideya, Endo Tomoyuki. Ketoacidosis at Hypoglycemic and Low Glucose Levels Associated with SGLT2 Inhibitor Use: A Descriptive Systematic Review of Published Cases.. Journal of clinical medicine. 2026. DOI: 10.3390/jcm15197595.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.